Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2025 08:01 ET | Source: Ashvattha Therapeutics

Ashvattha Therapeutics Accelerates Clinical Development Strategy with Leadership Appointment of Six Leading Retinal Specialists to Clinical Advisory Board

REDWOOD CITY, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
February 10, 2025 08:01 ET | Source: Ashvattha Therapeutics

Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow eyes of...
February 06, 2025 08:01 ET | Source: Ashvattha Therapeutics

Ashvattha to Present at Upcoming Angiogenesis, Exudation, and Degeneration 2025 and BIO CEO Conferences

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
January 13, 2025 08:01 ET | Source: Ashvattha Therapeutics

Ashvattha Therapeutics Announces $50 Million Financing Extension and Interim Phase 2 Ophthalmology Trial Results

Ashvattha receives additional financing up to $50 million with new lead investor Tribe Capital and existing investors led by Natural CapitalAshvattha’s at-home monthly subcutaneously-administered HDT...
June 10, 2024 08:30 ET | Source: Ashvattha Therapeutics

Presentation at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting Highlights Ashvattha Product Candidates for Neuroinflammation Imaging and Treatment

Preclinical data highlights the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE...
May 23, 2024 08:30 ET | Source: Ashvattha Therapeutics

Ashvattha Therapeutics to Present Preclinical Data at the CMSC and SNMMI Annual Meetings

Presentations highlight the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE preclinical...
February 22, 2024 08:30 ET | Source: Ashvattha Therapeutics

Ashvattha Therapeutics Announces First Patient Enrolled in Expanded Phase 1/2 Study of Imaging Agent 18F-OP-801 in Additional Neurological Indications

The study will evaluate the safety, tolerability, and ability of 18F-OP-801 to cross the blood-brain barrier and selectively target neuroinflammation in individuals with amyotrophic lateral sclerosis,...
February 14, 2024 08:30 ET | Source: Ashvattha Therapeutics

Ashvattha Therapeutics to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
January 04, 2024 08:30 ET | Source: Ashvattha Therapeutics

Ashvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical Operations

REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
November 20, 2023 08:30 ET | Source: Ashvattha Therapeutics

Ashvattha Therapeutics to Participate in Upcoming Ophthalmology Conferences

REDWOOD CITY, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...